Cargando…
A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980503/ http://dx.doi.org/10.1186/1745-6215-14-S1-O77 |
| _version_ | 1782479539693158400 |
|---|---|
| author | Maishman, Tom Stanton, Louise Davies, Andy Barrans, Sharon Worrillow, Lisa Mamot, Christoph Care, Matt Immins, Tikki Hamid, Debbie McMillan, Andrew Fields, Paul Jack, Andrew Johnson, Peter |
| author_facet | Maishman, Tom Stanton, Louise Davies, Andy Barrans, Sharon Worrillow, Lisa Mamot, Christoph Care, Matt Immins, Tikki Hamid, Debbie McMillan, Andrew Fields, Paul Jack, Andrew Johnson, Peter |
| author_sort | Maishman, Tom |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3980503 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-39805032014-04-24 A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy Maishman, Tom Stanton, Louise Davies, Andy Barrans, Sharon Worrillow, Lisa Mamot, Christoph Care, Matt Immins, Tikki Hamid, Debbie McMillan, Andrew Fields, Paul Jack, Andrew Johnson, Peter Trials Oral Presentation BioMed Central 2013-11-29 /pmc/articles/PMC3980503/ http://dx.doi.org/10.1186/1745-6215-14-S1-O77 Text en Copyright © 2013 Maishman et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Oral Presentation Maishman, Tom Stanton, Louise Davies, Andy Barrans, Sharon Worrillow, Lisa Mamot, Christoph Care, Matt Immins, Tikki Hamid, Debbie McMillan, Andrew Fields, Paul Jack, Andrew Johnson, Peter A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy |
| title | A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy |
| title_full | A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy |
| title_fullStr | A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy |
| title_full_unstemmed | A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy |
| title_short | A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy |
| title_sort | novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (remodl-b) with two interim analyses to explore safety and efficacy |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980503/ http://dx.doi.org/10.1186/1745-6215-14-S1-O77 |
| work_keys_str_mv | AT maishmantom anoveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT stantonlouise anoveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT daviesandy anoveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT barranssharon anoveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT worrillowlisa anoveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT mamotchristoph anoveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT carematt anoveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT imminstikki anoveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT hamiddebbie anoveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT mcmillanandrew anoveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT fieldspaul anoveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT jackandrew anoveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT johnsonpeter anoveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT maishmantom noveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT stantonlouise noveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT daviesandy noveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT barranssharon noveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT worrillowlisa noveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT mamotchristoph noveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT carematt noveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT imminstikki noveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT hamiddebbie noveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT mcmillanandrew noveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT fieldspaul noveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT jackandrew noveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy AT johnsonpeter noveladaptivetrialdesignrandomisedevaluationofmolecularguidedtherapyfordiffuselargebcelllymphomawithbortezomibremodlbwithtwointerimanalysestoexploresafetyandefficacy |